Global Prostate Health Market 2022-2032

1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Fact.MR Analysis and Recommendations

2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations

3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Prostate Health Demand
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ Mn)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends

4.1. Global Prostate Health Market (US$ Mn)
4.2. Prostate Health Market Opportunity Assessment (US$ Mn)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Global Prostate Health Market Growth
4.5.3. Prostate Health Adoption Rate, by Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Prostate Health Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking

6.1. Historical Market Analysis, 2015-2021
6.2. Current and Future Market Projections, 2022-2032
6.3. Y-o-Y Growth Trend Analysis

7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis

8.1. Introduction/Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2015-2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2022-2032
8.3.1. Prostate Cancer
8.3.1.1. AR Directed Therapies
8.3.1.2. Hormone ADT
8.3.1.3. Cytotoxic Agents
8.3.1.4. PARP Inhibitors
8.3.1.5. Others
8.3.2. Benign Prostate Hyperplasia
8.3.2.1. Alpha Blockers
8.3.2.1.1. Alfuzosin
8.3.2.1.2. Doxazosin
8.3.2.1.3. Tamsulosin
8.3.2.1.4. Silodosin
8.3.2.1.5. Other Alpha Blockers
8.3.2.2. 5 Alpha Reductase
8.3.2.2.1. Finasteride
8.3.2.2.2. Dutasteride
8.3.2.3. Others
8.3.3. Prostatitis
8.3.3.1. Prescription
8.3.3.2. Over the Counter
8.4. Market Attractiveness Analysis By Disease Indication

9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021
9.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. Asia Pacific
9.3.5. Middle East and Africa (MEA)
9.4. Market Attractiveness Analysis By Region

10.1. Introduction
10.2. Pricing Analysis
10.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021
10.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
10.4.1. By Country
10.4.1.1. U.S.
10.4.1.2. Canada
10.4.2. By Disease Indication
10.5. Market Attractiveness Analysis
10.5.1. By Country
10.5.2. By Disease Indication

11.1. Introduction
11.2. Pricing Analysis
11.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021
11.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
11.4.1. By Country
11.4.1.1. Brazil
11.4.1.2. Mexico
11.4.1.3. Rest of Latin America
11.4.2. By Disease Indication
11.5. Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Disease Indication

12.1. Introduction
12.2. Pricing Analysis
12.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021
12.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
12.4.1. By Country
12.4.1.1. Germany
12.4.1.2. France
12.4.1.3. U.K.
12.4.1.4. Italy
12.4.1.5. Benelux
12.4.1.6. Nordic Countries
12.4.1.7. Rest of Europe
12.4.2. By Disease Indication
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Disease Indication

13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021
13.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
13.4.1. By Country
13.4.1.1. China
13.4.1.2. Japan
13.4.1.3. South Korea
13.4.1.4. Rest of Asia Pacific
13.4.2. By Disease Indication
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Disease Indication

14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021
14.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
14.4.1. By Country
14.4.1.1. GCC Countries
14.4.1.2. South Africa
14.4.1.3. Turkey
14.4.1.4. Rest of Middle East and Africa
14.4.2. By Disease Indication
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Disease Indication

15.1. Introduction
15.1.1. Market Value Proportion Analysis, By Key Countries
15.1.2. Global Vs. Country Growth Comparison
15.2. US Prostate Health Market Analysis
15.2.1. Value Proportion Analysis by Market Taxonomy
15.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.2.2.1. By Disease Indication
15.3. Canada Prostate Health Market Analysis
15.3.1. Value Proportion Analysis by Market Taxonomy
15.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.3.2.1. By Disease Indication
15.4. Mexico Prostate Health Market Analysis
15.4.1. Value Proportion Analysis by Market Taxonomy
15.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.4.2.1. By Disease Indication
15.5. Brazil Prostate Health Market Analysis
15.5.1. Value Proportion Analysis by Market Taxonomy
15.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.5.2.1. By Disease Indication
15.6. Germany Prostate Health Market Analysis
15.6.1. Value Proportion Analysis by Market Taxonomy
15.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.6.2.1. By Disease Indication
15.7. France Prostate Health Market Analysis
15.7.1. Value Proportion Analysis by Market Taxonomy
15.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.7.2.1. By Disease Indication
15.8. Italy Prostate Health Market Analysis
15.8.1. Value Proportion Analysis by Market Taxonomy
15.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.8.2.1. By Disease Indication
15.9. BENELUX Prostate Health Market Analysis
15.9.1. Value Proportion Analysis by Market Taxonomy
15.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.9.2.1. By Disease Indication
15.10. UK Prostate Health Market Analysis
15.10.1. Value Proportion Analysis by Market Taxonomy
15.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.10.2.1. By Disease Indication
15.11. Nordic Countries Prostate Health Market Analysis
15.11.1. Value Proportion Analysis by Market Taxonomy
15.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.11.2.1. By Disease Indication
15.12. China Prostate Health Market Analysis
15.12.1. Value Proportion Analysis by Market Taxonomy
15.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.12.2.1. By Disease Indication
15.13. Japan Prostate Health Market Analysis
15.13.1. Value Proportion Analysis by Market Taxonomy
15.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.13.2.1. By Disease Indication
15.14. South Korea Prostate Health Market Analysis
15.14.1. Value Proportion Analysis by Market Taxonomy
15.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.14.2.1. By Disease Indication
15.15. GCC Countries Prostate Health Market Analysis
15.15.1. Value Proportion Analysis by Market Taxonomy
15.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.15.2.1. By Disease Indication
15.16. South Africa Prostate Health Market Analysis
15.16.1. Value Proportion Analysis by Market Taxonomy
15.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.16.2.1. By Disease Indication
15.17. Turkey Prostate Health Market Analysis
15.17.1. Value Proportion Analysis by Market Taxonomy
15.17.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
15.17.2.1. By Disease Indication
15.17.3. Competition Landscape and Player Concentration in the Country

16.1. Market Analysis by Tier of Companies
16.2. Market Concentration
16.3. Market Share Analysis of Top Players
16.4. Market Presence Analysis
16.4.1. By Regional footprint of Players
16.4.2. Product footprint by Players

17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Competition Deep Dive
17.3.1. GLAXOSMITHKLINE
17.3.1.1. Overview
17.3.1.2. Product Portfolio
17.3.1.3. Sales Footprint
17.3.1.4. Strategy Overview
17.3.2. ASTELLAS PHARMA
17.3.2.1. Overview
17.3.2.2. Product Portfolio
17.3.2.3. Sales Footprint
17.3.2.4. Strategy Overview
17.3.3. ALLERGAN
17.3.3.1. Overview
17.3.3.2. Product Portfolio
17.3.3.3. Sales Footprint
17.3.3.4. Strategy Overview
17.3.4. MERCK
17.3.4.1. Overview
17.3.4.2. Product Portfolio
17.3.4.3. Sales Footprint
17.3.4.4. Strategy Overview
17.3.5. ELI LILLY AND COMPANY
17.3.5.1. Overview
17.3.5.2. Product Portfolio
17.3.5.3. Sales Footprint
17.3.5.4. Strategy Overview
17.3.6. ABBOTT LABORATORIES
17.3.6.1. Overview
17.3.6.2. Product Portfolio
17.3.6.3. Sales Footprint
17.3.6.4. Strategy Overview
17.3.7. JOHNSON & JOHNSON SERVICES, INC.
17.3.7.1. Overview
17.3.7.2. Product Portfolio
17.3.7.3. Sales Footprint
17.3.7.4. Strategy Overview
17.3.8. ABBVIE
17.3.8.1. Overview
17.3.8.2. Product Portfolio
17.3.8.3. Sales Footprint
17.3.8.4. Strategy Overview
17.3.9. SANOFI
17.3.9.1. Overview
17.3.9.2. Product Portfolio
17.3.9.3. Sales Footprint
17.3.9.4. Strategy Overview
17.3.10. PFIZER, INC.
17.3.10.1. Overview
17.3.10.2. Product Portfolio
17.3.10.3. Sales Footprint
17.3.10.4. Strategy Overview